Syschem (India)
Healthcare
531173 BSE
₹33.34 −0.69 (−2.03%)
- P/E
- 23.48
Close 4 Nov 2026 ₹33.34 −25.33 −43.2% 1Y
Start ₹58.67
Key Fundamentals
MicrocapPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of · EPS basis: Standalone · TTM
- ROCE
- 15.90%
- Debt to Equity
- 0.00
- EPS (TTM)
- ₹1.42
- Book Value
- ₹26.05
- Market Cap
- —
- P/E (TTM)
- 23.48
- P/B
- 1.28
- ROE
- 10.20%
- Dividend Yield
- 0.00%
- EBITDA
- ₹21.10 Cr
- 52W High
- ₹60.95
- 52W Low
- ₹28.81
- Day Range
- ₹32.50 – ₹34.00
- Volume
- 11,740
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
51 Average
Data confidence 100/100
Category scores
- Quality
- 53
- Average
- Returns, margins, earnings quality 22% weight
- Valuation
- 49
- Average
- Cheap vs sector & own history 24% weight
- Growth
- 96
- Strong
- Sales & profit trajectory 9% weight
- Financial Health
- 52
- Average
- Solvency, leverage, coverage 9% weight
- Momentum
- 14
- Poor
- Trend strength, vol-adjusted 12% weight
- Ownership
- 48
- Average
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
6- Company is almost debt free.
- Company is expected to give good quarter
- Company has delivered good profit growth of 32.4% CAGR over last 5 years
- Promoter holding has increased by 2.52% over last quarter.
- Company's median sales growth is 70.0% of last 10 years
- Company's working capital requirements have reduced from 40.8 days to 29.3 days
Weaknesses
2- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 6.41% over last 3 years.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bearish | 12 | 7 | 0 |
| Oscillators | Bearish | 2 | 7 | 0 |
| Moving Averages | Strong Bearish | 10 | 0 | 0 |
Oscillators
Bearish
Bearish
2
Neutral
7
Bullish
0
Overall
Strong Bearish
Bearish
12
Neutral
7
Bullish
0
Moving Averages
Strong Bearish
Bearish
10
Neutral
0
Bullish
0
Key readings
- RSI (14)
- 46.33
- Neutral
- MACD (12,26,9)
- −0.18
- Bearish
- SMA (50)
- 33.49
- Bearish
- SMA (200)
- 42.64
- Bearish
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.
Revenue
| 10Y | +64.32% |
|---|---|
| 5Y | +53.21% |
| 3Y | +71.40% |
| 1Y | +72.89% |
| TTM | +62.29% |
Net profit
| 10Y | Turned to profit |
|---|---|
| 5Y | Turned to profit |
| 3Y | +30.06% |
| 1Y | Zero base |
| TTM | +208.54% |
Operating cash flow
| 10Y | Zero base |
|---|---|
| 5Y | +14.87% |
| 3Y | Turned positive |
| 1Y | Turned positive |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | +28.66 pp |
|---|---|
| 5Y | +11.01 pp |
| 3Y | −4.23 pp |
| 1Y | +2.46 pp |
| TTM | +1.75 pp |
Revenue by year
| Mar 2017 | ₹13.00 Cr |
|---|---|
| Mar 2018 | ₹67.00 Cr |
| Mar 2019 | ₹93.00 Cr |
| Mar 2020 | ₹77.00 Cr |
| Mar 2021 | ₹68.00 Cr |
| Mar 2022 | ₹59.00 Cr |
| Mar 2023 | ₹114 Cr |
| Mar 2024 | ₹199 Cr |
| Mar 2025 | ₹332 Cr |
| Mar 2026 | ₹574 Cr |
Net profit by year
| Mar 2017 | −₹1.00 Cr |
|---|---|
| Mar 2018 | ₹0.00 Cr |
| Mar 2019 | ₹1.00 Cr |
| Mar 2020 | −₹2.00 Cr |
| Mar 2021 | −₹6.00 Cr |
| Mar 2022 | −₹2.00 Cr |
| Mar 2023 | ₹5.00 Cr |
| Mar 2024 | ₹3.00 Cr |
| Mar 2025 | ₹0.00 Cr |
| Mar 2026 | ₹11.00 Cr |
Quarterly Results
₹ Cr| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 43.1 | 37.11 | 43.74 | 74.71 | 87.53 | 47.52 | 77.76 | 119 | 109 | 104 | 142 | 219 | 109 |
| Expenses | 40.65 | 35.26 | 42.66 | 73.09 | 86.72 | 47.45 | 76.56 | 117 | 107 | 100 | 136 | 210 | 109 |
| Operating Profit | 2.45 | 1.85 | 1.08 | 1.62 | 0.81 | 0.07 | 1.2 | 1.9 | 2.46 | 3.3 | 5.96 | 9.37 | 0.54 |
| OPM % | 5.68% | 4.99% | 2.47% | 2.17% | 0.93% | 0.15% | 1.54% | 1.6% | 2.25% | 3.19% | 4.21% | 4.27% | 0.49% |
| Other Income | 0 | 0 | 0.01 | 0.15 | 0.01 | 0 | 0.02 | 0.02 | 0.01 | 0.01 | 0 | 0 | 0.05 |
| Interest | 0.1 | 0.03 | 0.11 | 0.01 | 0 | 0.03 | 0.04 | 0 | 0.04 | 0.01 | 0.17 | 2.04 | 0.49 |
| Depreciation | 0.68 | 0.7 | 0.74 | 0.67 | 0.68 | 0.68 | 0.68 | 0.91 | 0.76 | 0.76 | 0.82 | 1.73 | 1.56 |
| PBT | 1.67 | 1.12 | 0.24 | 1.09 | 0.14 | −0.64 | 0.5 | 1.01 | 1.67 | 2.54 | 4.97 | 5.6 | −1.46 |
| Tax % | 0% | 0% | 0% | 123.85% | 0% | 0% | 0% | 54.46% | 0% | 25.59% | 15.9% | 68.93% | 15.07% |
| Net Profit | 1.68 | 1.12 | 0.23 | −0.26 | 0.14 | −0.64 | 0.5 | 0.46 | 1.67 | 1.9 | 4.17 | 1.74 | −1.67 |
| EPS (₹) | 0.42 | 0.28 | 0.06 | −0.07 | 0.04 | −0.16 | 0.13 | 0.11 | 0.38 | 0.44 | 0.96 | 0.36 | −0.34 |
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 11 | 4 | 13 | 67 | 93 | 77 | 68 | 59 | 114 | 199 | 332 | 574 | 574 |
| Expenses | 14 | 5 | 12 | 63 | 89 | 77 | 73 | 58 | 105 | 192 | 328 | 553 | 554 |
| Operating Profit | −3 | −1 | 0 | 3 | 4 | 0 | −5 | 1 | 9 | 7 | 4 | 21 | 19 |
| OPM % | −23% | −24% | 0.4% | 4.5% | 4.4% | −0.1% | −7% | 0.9% | 8% | 3.5% | 1.2% | 3.7% | 3.3% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 4 | 5 |
| PBT | −5 | −3 | −2 | 1 | 2 | −2 | −7 | −2 | 6 | 4 | 1 | 15 | 12 |
| Tax % | −26% | −27% | −30% | 43% | 50% | −16% | −24% | −22% | 27% | 33% | 54% | 26% | — |
| Net Profit | −4 | −2 | −1 | 0 | 1 | −2 | −6 | −2 | 5 | 3 | 0 | 11 | 6 |
| EPS (₹) | −1.94 | −1.13 | −0.75 | 0.17 | 0.32 | −0.79 | −2.07 | −0.59 | 1.13 | 0.69 | 0.11 | 2.23 | 1.42 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 16 | 16 | 16 | 16 | 19 | 19 | 22 | 23 | 32 | 40 | 44 | 49 |
| Reserves | −6 | −8 | −10 | −8 | −8 | −10 | −15 | −16 | −10 | 17 | 48 | 73 |
| Borrowings | 28 | 27 | 22 | 20 | 16 | 17 | 16 | 2 | 2 | 0 | 0 | 0 |
| Other Liabilities | 13 | 12 | 16 | 29 | 35 | 36 | 55 | 51 | 69 | 107 | 126 | 169 |
| Total Liabilities | 51 | 47 | 44 | 58 | 62 | 62 | 77 | 60 | 93 | 164 | 217 | 292 |
| Fixed Assets | 34 | 32 | 30 | 29 | 27 | 28 | 30 | 32 | 31 | 31 | 53 | 68 |
| CWIP | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 4 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 16 | 15 | 14 | 28 | 35 | 34 | 46 | 28 | 62 | 129 | 164 | 224 |
| Total Assets | 51 | 47 | 44 | 58 | 62 | 62 | 77 | 60 | 93 | 164 | 217 | 292 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 1 | 0 | 6 | 0 | −2 | 3 | 4 | 1 | −8 | −26 | −10 | 8 |
| Investing | 0 | 0 | 0 | 0 | 2 | −4 | −4 | −1 | −2 | −6 | −22 | −20 |
| Financing | −2 | −1 | −7 | 0 | 0 | 0 | 0 | 0 | 11 | 32 | 34 | 18 |
| Net Cash Flow | −1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 6 |
| Free Cash Flow | 1 | 0 | 6 | −1 | −2 | 0 | −1 | −2 | −10 | −32 | −32 | −11 |
| CFO/OP | −56 | −53 | 12,760 | 9 | −24 | −3,456 | −40 | 107 | −79 | −348 | −238 | 54 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 187 | 272 | 124 | 47 | 21 | 47 | 31 | 21 | 135 | 126 | 99 | 92 |
| Inventory Days | 228 | 868 | 182 | 80 | 104 | 110 | 199 | 152 | 61 | 107 | 81 | 41 |
| Days Payable | 290 | 870 | 424 | 151 | 131 | 175 | 221 | 186 | 158 | 198 | 143 | 112 |
| Cash Conversion Cycle | 124 | 271 | −119 | −24 | −7 | −19 | 9 | −14 | 38 | 34 | 36 | 21 |
| Working Capital Days | −139 | −564 | −319 | −50 | −20 | −36 | −1 | −15 | 48 | 54 | 39 | 29 |
| ROCE % | −11% | −8% | −6% | 3% | 7% | −8% | −29% | −12% | 38% | 11% | 1% | 16% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Syschem insights
66 extracted metrics across FY10–FY27.
Documents
- 4 Aug 2026
- 4 Aug 2025
- General announcements 28 Oct 2026
Frequently Asked Questions about Syschem (India)
What does Syschem (India) Ltd do?
Incorporated in 1993, Syschem (India) Limited manufactures Active Pharmaceuticals Ingredients (APIs) and bulk drugs.
Where is Syschem (India) Ltd (SYSCHEM) listed?
Syschem (India) Ltd trades under code 531173 on the BSE.
Which sector does Syschem (India) Ltd belong to?
Syschem (India) Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Syschem (India) Ltd?
Syschem (India) Ltd trades at a PE ratio of 23.48 as of 4 Nov 2026, on earnings per share of ₹1.42, against a book value of ₹26.05 per share.
What is the 52-week high and low of Syschem (India) Ltd?
Over the last 52 weeks Syschem (India) Ltd has traded between ₹28.81 and ₹60.95 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Syschem (India) Ltd?
Syschem (India) Ltd reported a return on equity of 10.20%. Its debt-to-equity ratio is 0.00.
Company Information
Incorporated in 1993, Syschem (India) Limited manufactures Active Pharmaceuticals Ingredients (APIs) and bulk drugs.
Website syschem.in
Face Value ₹10
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/531173.md for Syschem (India) Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.